Compare Gilead Sciences, Inc. (GILD) vs Gitlab Inc (GTLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Gitlab Inc — how do they compare? Gilead Sciences, Inc. trades at $149.95 (market cap $182.40B), while Gitlab Inc trades at $54.51 (market cap $8.92B). The key difference: Gilead Sciences, Inc. is far larger — about 20.4× Gitlab Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Gitlab Inc for 62 Days on average.
| GILD | GTLB | |
|---|---|---|
Market Cap | $182.40B | $8.92B |
Volume | 4,469,821 | 4,716,893 |
Sector | Health | Technology |
52-Week High | $155.80 | $53.56 |
52-Week Low | $116.74 | $19.42 |
Typical Hold Time | 111 Days | 62 Days |
Enterprise Value | $205.46B | $7.66B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
GitLab (GTLB) trades at $51.99, up 0.7% on the day and near its 52-week high, supported by a bullish technical outlook and strong Q2 2026 earnings beats. Revenue growth accelerated to 21.3% year-over-year, with the company raising full-year guidance amid robust AI-driven demand for its DevSecOps platform. However, the stock trades at a high P/E ratio of 521.22, reflecting premium valuation despite negative net income margins.
The investment case hinges on GitLab's execution in monetizing AI and enterprise expansion, but risks include sustained profitability challenges and competitive pressure. Analysts are mixed with a Hold consensus, yet recent news highlights sales momentum and institutional interest, suggesting potential upside if growth targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
